Study identification

EU PAS number

EUPAS1000000599

Study ID

1000000599

Official title and acronym

DARWIN EU® - Eye disorders in women with breast cancer treated with anastrozole, letrozole or tamoxifen

DARWIN EU® study

Yes

Study countries

Croatia
Finland
Germany
Spain
United Kingdom

Study description

This study aims to describe the incidence of ocular adverse events after the use of anastrozole, letrozole or tamoxifen treatments in pre- and postmenopausal women with breast cancer across several European countries.

Study status

Finalised
Research institutions and networks

Institutions

Networks

Contact details

Anton Barchuk

Primary lead investigator

Study timelines

Date when funding contract was signed

Planned:
Actual:

Study start date

Planned:
Actual:

Date of final study report

Planned:
Actual:
Sources of funding
EMA
Regulatory

Was the study required by a regulatory body?

Yes

Is the study required by a Risk Management Plan (RMP)?

Not applicable